1	Title: Prognostic value of an integrated human papilloma virus and immunoscore model to
2	predict survival in vulva squamous cell carcinoma
3	
4	Rammah Elnour ¹ , Ingjerd Helstrup Hindenes ² , Malene Færevaag ² , Ingrid Benedicte Moss
5	Kolseth ³ , Liv Cecilie Vestrheim Thomsen ^{3,4} , Anne Christine Johannessen ^{1,5} , Daniela Elena
6	Costea ^{1,5} , Line Bjørge ^{3,4*} , Harsh Nitin Dongre ^{1#*}
7	
8	¹ Center for Cancer Biomarkers CCBIO and Gade Laboratory of Pathology, Department of
9	Clinical Medicine, University of Bergen, Bergen, Norway. ² Department of Chemistry,
10	University of Bergen, Bergen, Norway. ³ Department of Obstetrics and Gynecology, Haukeland
11	University Hospital, Bergen, Norway. ⁴ Center for Cancer Biomarkers CCBIO, Department of
12	Clinical Science, University of Bergen, Bergen, Norway. ⁵ Department of Pathology, Laboratory
13	Clinic, Haukeland University Hospital, Bergen, Norway.
14	
15	*These authors contributed equally.
16	
17	[#] Corresponding author: <u>harsh.dongre@uib.no</u>
18	Jonas Lies Vei 65, Department of Clinical Medicine, University of Bergen, 5021 Norway
19	
20	Running title: Prognostic impact of immunoscore in VSCC
21	
22	Keywords: immunoscore, prognostic marker, vulva squamous cell carcinoma, immune-
23	oncology, digital pathology

24 Abstract:

Background: While the prognostic value of immune-related biomarkers is well characterized in
many solid tumors, their significance in vulva squamous cell carcinoma (VSCC) remains unclear.
Here, we report a comprehensive analysis of programmed death-ligand 1 (PD-L1) and immune
cell infiltrates in VSCC and establish immunoscore models for classification of the disease.

29

Methods: Archival tissues, immunohistochemistry, and digital quantification were used to 30 31 investigate the number of CD4+, CD8+, CD68+, CD14+, FoxP3+, and PD-L1+ cells in epithelial and stromal compartments of VSCC (n=117). Immunoscores were developed using these 32 parameters and applying the least absolute shrinkage and selection operator (LASSO) to identify 33 predictors of survival. Immunoscores were integrated with HPV status, as determined by mRNA 34 in situ hybridization, to construct internally validated nomograms. The models were assessed using 35 Harrell's concordance-index (c-index), calibration plots, Kaplan-Meier curves, and decision curve 36 analysis. 37

38

39 **Results:** Advanced VSCC (FIGO stage III/IV) was characterized by high numbers of CD68+ macrophages and PD-L1+ cells (Spearmans' correlation, ρ >0.80) in the epithelium. PD-L1 status 40 independently predicted poor progression free survival (PFS) (HR=1.80, (95% CI (1.024-3.170), 41 42 p=0.041). High stromal CD68+ or CD14+ myeloid cell infiltration was associated with poor PFS and disease specific survival (DSS) (p<0.05). Immunological parameters were used to determine 43 immunoscores. Immunoscore^{PFS} and immunoscore^{DSS} were independent prognosticators of PFS 44 (p=0.001) and DSS (p=0.007) respectively. Integrating immunoscores with HPV status (IS-HPV 45 index) improved the prognostic impact of the models. The c-index of IS-HPV index^{PFS} was 0.750 46

47	for prediction of PFS compared to 0.666 for HPV status and 0.667 for immunoscore ^{PFS} . The c-
48	index of IS-HPV index DSS was 0.752 for predicting DSS compared to 0.631 for HPV status and
49	0.715 for immunoscore ^{DSS} .
50	
51	Conclusion: In summary, an index based on HPV status and an immunoscore built on PD-L1
52	expression and immune cell infiltrates could potentially serve as a prognostic tool to refine risk
53	stratification in VSCC. Further validation is warranted to demonstrate clinical utility.
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	

70 WHAT IS ALREADY KNOWN ON THIS TOPIC

Immunoscores have emerged as promising biomarkers in several solid tumors, however the 71 72 prognostic potential of these models in vulva squamous cell carcinoma (VSCC) remains unexplored. Immunoscores are traditionally based on quantification of CD3+ and CD8+ T 73 lymphocytes within the tumor core and invasive margin. However recent studies have highlighted 74 75 the prognostic significance of additional immune cell subtypes, such as macrophages, in predicting patient survival. Advanced quantitative methods that enable the determination of immunoscores, 76 77 incorporating expression of immune checkpoint proteins and infiltration of various immune cell 78 populations within tumors, warrant further investigation.

79

80 WHAT THIS STUDY ADDS

This study investigates PD-L1 expression and distinct T lymphocyte and myeloid cell subsets 81 82 within the spatial architecture of VSCC to identify immunological markers with prognostic value. 83 Computational analysis identified PD-L1+ cells, CD8+ T lymphocytes, FoxP3+ T lymphocytes, and CD14+ myeloid cells as significant survival predictors in VSCC, leading to the development 84 85 of immunoscores. These immunoscores demonstrated superior predictive performance compared 86 to the individual parameters used to construct the models. Moreover, integrating immunoscores with HPV status and constructing, for the first time, an immunoscore-HPV index nomogram 87 88 enhanced the prognostic accuracy and net benefit of the models.

89

90 HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

91 The immunoscore-HPV index proposed in this study holds potential as a rapid diagnostic tool to
92 enhance risk stratification in VSCC and facilitate the identification of patients who may benefit

93	from less aggressive treatment approaches. Incorporating immunoscores with clinicopathological
94	or molecular features linked to carcinogenesis in prognostic models could improve classification
95	strategies in VSCC and other cancer types.
96	
97	
98	
99	
100	
101	
102	
103	
104	
105	
106	
107	
108	
109	
110	
111	
112	
113	
114	
115	

116 Introduction

Vulvar squamous cell carcinoma (VSCC) is a relatively rare but heterogenous disease, with 47,300 117 new cases and 18,600 deaths globally each year (1). VSCC accounts for six percent of all 118 gynecological malignancies (2), and its incidence rates have been increasing steadily (3). Despite 119 120 recent surgical advances, 12-37% of VSCC patients experience disease recurrence, with a fiveyear survival rate ranging between 30-60% (4, 5). For metastatic disease, the five-year survival 121 122 rate is reported to be below 30% (6). Beyond surgical resection and radiochemotherapy, treatment options are limited, especially for managing advanced stage disease (7). While precision medicine 123 guided by molecular subtyping has been adopted in various cancers, efforts to incorporate 124 molecular risk stratification in VSCC have only recently begun. VSCC is characterized by two 125 distinct etiopathogenic pathways: high risk human papilloma virus (HPV)-associated VSCC, 126 driven by the integration of the HPV genome and the expression of the E6/E7 oncoproteins, and 127 128 HPV-independent VSCC which often arises in the context of inflammatory vulvar lesions such as 129 lichen sclerosus (8, 9). Studies have shown that HPV-associated VSCC has better prognosis compared to the more common HPV-independent VSCC (10, 11). Thus, identifying biomarkers 130 131 to predict survival especially in HPV-independent VSCC is urgently needed.

132

The cancer immune contexture, encompassing the infiltration of various immune cell populations and the expression of immune checkpoint proteins (12), is currently being analyzed to identify biomarkers with predictive and prognostic potential in several gynecological cancers (13). Targeting programmed cell death protein-1 (PD-1) with an immune checkpoint inhibitor, has been associated with prolonged survival in a subset of patients with advanced, recurrent, or metastatic VSCC (14). This suggests that modulating the tumor immune microenvironment (TIME) is a

viable therapeutical strategy with significant impact on survival, however immunotherapy has not 139 yet been included into standard treatment regimens. Furthermore, the prognostic value of immune 140 141 checkpoints and specific immune cell subsets within the spatial architecture of VSCC remains unclear (15-18). Recently, studies have indicated that the TIME can be leveraged to establish 142 cancer classification strategies with clinical utility. Indeed, the immunoscore became the first 143 144 standardized consensus assay for classifying hot and cold tumors based on the infiltration of CD3+ and CD8+ T lymphocytes in the tumor core and invasive margin in colon cancer (19-21). There 145 146 have only been a few studies focused on establishing prognostic models, such as nomograms, 147 capable of stratifying VSCC patients and predicting survival. To our knowledge, immunoscore models based on spatially resolved immunological features have yet to be reported for this disease. 148 Developing prognostic tools based on compartment-specific infiltration patterns of immune cell 149 150 subsets in both HPV-associated and HPV-independent tumors may enhance personalized medicine 151 and allow for individual risk stratification of VSCC.

152

In this study, we report a comprehensive *in-situ* analysis of PD-L1 expression and distinct T lymphocyte- and myeloid cell populations in VSCC, revealing components of the immune landscape associated with disease progression. Using these immunological features, we established a novel immunoscore model for VSCC. Further, we integrated the immunoscore with HPV status and assessed the prognostic value of the resulting immunoscore-HPV status index in predicting risk progression in VSCC.

159

160

162 Materials and Methods

163 **Study population**

One hundred and thirty-eight patients diagnosed with VSCC and undergoing treatment at 164 Haukeland University Hospital (HUS), Bergen, Norway between 1999-2017 were included in this 165 166 retrospective study. The patients were treatment naïve, prospectively sampled, and staged according to the FIGO (International Federation of Gynecology and Obstetrics) criteria. Written 167 168 consent was obtained from all participants prior to inclusion. Most of the patients were registered 169 in Bergen Gynecologic Cancer Biobank (GYNCAN). A few tumor samples were obtained from the diagnostic biobank at the Department of Pathology (HUS). Cases with missing sample, 170 insufficient epithelial and/or stromal tissue material, neoadjuvant treatment, or withdrawn consent 171 were excluded from this study (n = 21). Clinicopathological data were extracted from medical 172 journals as previously described (10). This study was approved by the Regional Committee for 173 Medical and Health Research Ethics Norway (REK Nos: 2017/279 and 2014/1907). 174

175

176 Sample collection and tissue microarray construction

177 Archival formalin-fixed paraffin embedded (FFPE) sections were hematoxylin and eosin stained to select the areas for construction of tissue microarrays (TMA). A minimum of two 1 mm cylinder 178 biopsies from the tumor front areas of primary tumors, recurrences, and metastases were punched 179 180 out and placed in paraffin blocks using a precision instrument (Beecher Instruments, Silver Spring, MD, USA). TMA sections of 4-um thickness were cut using a microtome (Leica Microsystems, 181 Wetzlar, Germany) and mounted on Superfrost Plus glass slides (Thermo Fisher Scientific, 182 Waltham, MA, USA). Slides were then incubated at 56°C for 24 hours and stored at 4°C in 183 preparation for immunostaining. 184

185 Immunohistochemistry and HPV detection

Immunohistochemistry (IHC) was performed on TMA sections using a Ventana Benchmark 186 ULTRA Autostainer (Roche Tissue Diagnostics, Tucson, AZ, USA), according to the 187 manufacturer's instruction. CD4+ helper T cells, CD8+ cytotoxic T cells, CD68+ macrophages, 188 CD14+ monocytes, FoxP3+ regulatory T cells, and PD-L1+ cells were identified using the 189 190 antibodies summarized in Supplementary Table 1. The OptiView DAB IHC detection kit (Roche Tissue Diagnostics) was used for detection of primary antibodies and visualization. The detailed 191 192 protocols for p16 and p53 IHC, HPV DNA PCR, and HPV mRNA in situ hybridization (ISH) are 193 described elsewhere (10, 22).

194

195 Digital quantification and evaluation

Immunostained TMAs were digitally scanned using a Hamamatsu NanoZoomer-XR whole slide 196 scanner (Hamamatsu Photonics, Hamamatsu City, Japan) at 40x magnification and analyzed using 197 the open-source software QuPath (version 0.4.0) (23). For digital quantification, epithelial and 198 stromal compartments of TMA cores were manually annotated using QuPath tools (Supplementary 199 Figure 1A). QuPath automated algorithms for setting vector stains and color-deconvolution were 200 201 then used to detect cell nuclei and immune markers based on adjusted hematoxylin and 3, 3'diaminobenzidine (DAB) thresholds (Supplementary Figure 1B-C). The hematoxylin and DAB 202 203 thresholds were maintained between slides of each marker to acquire homogenous results. Routine 204 calibration was performed together with a qualified pathologist (DEC). The number of positive cells for each marker per mm² compartment was then calculated and the mean of all cores from 205 206 each individual patient sample was used for analysis. CD4+, CD8+, CD68+, CD14+, and FoxP3+ 207 immune cells were dichotomized into high and low infiltration based on median positive cell

counts per mm² epithelial or stromal compartment for each respective marker (Supplementary Figure 2). PD-L1 status was determined by using both the tumor proportion score method (TPS: number of PD-L1+ tumor cells divided by the total number of tumor cells multiplied by 100) and the combined positive score method (CPS: total number of PD-L1+ tumor cells and PD-L1+ stromal cells divided by the total number of tumor cells multiplied by 100) (24). Cases with a discriminative cut-off value of TPS > 1 or CPS > 1 were considered PD-L1 positive.

214

215 Statistical analysis

216 All statistical analysis and data visualization was performed using IBM SPSS 25.0 (SPSS, Chicago, IL) and R (version 4.3.0 or higher). Differences concerning infiltration of cells within 217 epithelial or stromal compartments were investigated using the Wilcoxon-Signed Rank Test. The 218 219 chi-squared test was used to explore associations between immune subsets and clinicopathological features. The Mann-Whitney U test was used to study differences in the number of infiltrating cells 220 221 based on clinicopathological features. Correlations between different cell populations were analyzed using the Spearmans' rank correlation coefficient. Survival analysis was performed using 222 the R packages "survival" (v.3.5-7) and "survminer" (v.0.4.9) for Kaplan-Meier estimator, log-223 224 rank test, and Cox regression models. p-values ≤ 0.05 were considered statistically significant. 225 Parameters that were significant in univariate analysis were further analyzed in multivariate 226 analysis. Progression free survival (PFS) was calculated as the time in months from the date of 227 termination of primary treatment to the date of recurrence or death. Disease specific survival (DSS) was calculated as the time in months from date of primary treatment to the date of death from 228 229 disease. Patients alive at last contact or patients deceased from other causes were censored. The 230 "glmnet" package (v.4.1-8) was used for the least absolute shrinkage and selection operator

231	(LASSO) to determine immunoscores based on CD4+, CD8+, CD68+, CD14+, FoxP3+, and PD-
232	L1+ expression in epithelial and stromal compartments of tumors. Immunoscores were
233	dichotomized using the maximally selected rank statistics method in the survminer package or by
234	median values. Immunoscores and HPV mRNA ISH were used to construct logistic regression
235	models and nomograms using the "rms" (v.6.7-1) package and "dcurves" (v.0.4.0) was used for
236	decision curve analysis.
237	
238	
239	
240	
241	
242	
243	
244	
245	
246	
247	
248	
249	
250	
251	
252	
253	

254 Results

Advanced stage VSCC and HPV-independent tumors displayed higher expression of PD-L1 and infiltration of CD68+ macrophages

257 The number of infiltrating CD4+, CD8+, CD68+, CD14+, or FoxP3+ cells (Figure 1A) were higher 258 in the stroma of VSCC compared to the epithelium (p < 0.05), however no significant difference 259 was observed in the amount of PD-L1+ cells (Supplementary Figure 3A). CD68+ and CD14+ 260 myeloid cells were the most prevalent immune cell subsets (Supplementary Table 2), and higher 261 infiltration of these cells in the epithelium was linked to clinicopathological features including tumor size (Supplementary Table 3). Advanced tumors (FIGO stage III and IV) were more highly 262 populated with epithelial PD-L1+ and CD68+ cells (Figure 1B). Accordingly, tumors larger in size 263 (> 4cm) or with lymph node metastasis were found to have increased numbers of these subsets in 264 the epithelium. Larger tumors also demonstrated higher infiltration of CD14+ monocytes, in both 265 the epithelium and stroma (Supplementary Figure 3B-C). Within the advanced VSCC subgroup, 266 HPV-independent tumors (as determined by HPV mRNA ISH) demonstrated a higher number of 267 PD-L1+ cells in the stroma compared to HPV-associated counterparts (p < 0.05) (Figure 1C). 268 269 Moreover, HPV-independent tumors demonstrated higher stromal infiltration of both CD68+ and CD14+ myeloid subsets in early stage VSCC (FIGO stage I and II). Further, the number of 270 271 epithelial CD68+ macrophages and stromal CD14+ monocytes were higher in tumors with TP53 272 mutations and no p16 expression (p53+/p16-) compared to the p53-/p16+ subtype (Supplementary Figure 3D-E). Among T lymphocyte subsets, CD8+ cytotoxic T cells were the predominant group, 273 whereas the infiltration of CD4+ helper T cells was low, particularly in the epithelial compartments 274 (Supplementary Table 2). Apart from FoxP3+ regulatory T cells, which were associated with 275 disease specific survival (p < 0.05), no significant associations were found between infiltration of 276

T cell subsets and clinicopathological features (Supplementary Table 3). To explore the correlations between PD-L1 and immune cell infiltration in the epithelial and stromal compartments, the Spearmans' rank correlation coefficient was utilized. The number of PD-L1+ cells was positively correlated with all immune subsets in both compartments (p < 0.05) (Figure 1D). The strongest correlation was identified between PD-L1+ cells and CD68+ macrophages in the epithelium ($\rho = 0.80$) and stroma ($\rho = 0.71$) (Figure 1E-F) whereas CD4+, CD8+, CD14+, and FoxP3+ infiltrates were moderately correlated with PD-L1+ ($\rho = 0.43-0.58$).

284

285 **Positive PD-L1 status independently predicted poor PFS**

Traditional prognostic factors for VSCC, including age and HPV status, were significantly linked 286 to survival in this cohort (Supplementary Table 4). The analysis was expanded to assess the 287 288 prognostic impact of stratifying patients by immune cell infiltration and PD-L1 status. Kaplan-289 Meier analysis revealed positive PD-L1 status (TPS > 1) or high stromal infiltration of CD14+ monocytes to be associated with poor PFS (log rank test: p = 0.002 and p = 0.015, respectively) 290 (Figure 2A). This was also the case for high infiltration of CD68+ macrophages in stromal or 291 epithelial compartments (log rank test: p = 0.019 and p = 0.042 respectively) (Figure 2A and 292 293 Supplementary Figure 4A-B). Furthermore, high infiltration of either CD68+ macrophages or CD14+ monocytes in the stroma predicted poor DSS (log rank test: p = 0.011 and p = 0.027294 295 respectively). In contrast, high epithelial infiltration of FoxP3+ T cells was associated with more 296 favorable DSS outcomes (log rank test: p = 0.036) (Figure 2B). Results from the univariate Cox analysis aligned with these findings however, after adjusting for age and HPV status in the 297 298 multivariate Cox analysis, only PD-L1 status (TPS > 1) remained an independent prognostic 299 indicator for PFS (HR = 1.80, p = 0.041). In contrast PD-L1 status as determined by CPS > 1, was

not significantly associated with PFS (Table 1). None of the investigated markers demonstrated 300 independent prognostic value for DSS after adjusting for confounders. In this cohort, 58/117 301 primary tumors (49.6%), 21/29 recurrences (72.4%), and 25/36 metastatic lesions (69.4%) were 302 PD-L1 positive (TPS > 1). Moreover, variations in PD-L1 status were evident between primary 303 tumors and their respective recurrent or metastatic counterparts (Figure 2C-D). Within the cohort 304 305 of PD-L1 negative primary tumors, eight of the matched recurrences (61.5%) and four of the matched metastases (30.8%) were PD-L1 positive respectively (Figure 2E-F). Consistent with PD-306 L1+ infiltration patterns, positive PD-L1 status was associated with HPV-independent VSCC and 307 308 the p53+/p16- subtype (Table 2).

309

310 Construction of immunoscore models with independent prognostic value for PFS and DSS 311 To further evaluate prognostic epithelial and stromal immune features and establish a combined immunoscore, the LASSO Cox regression model was used in which tuning parameter (λ) values 312 were selected by 10-fold cross-validation (via minimum criteria) (Figure 3A, Supplementary 313 314 Figure 5A). This identified four non-zero coefficients based on PFS and five non-zero coefficients based on DSS (Figure 3B, Supplementary Figure 5B). Immunoscores were subsequently 315 calculated using these coefficients: immunoscore^{PFS} = (1.8609 x number of epithelial PD-L1+316 $cells/mm^2$) + (-4.5255 x number of epithelial CD8+ $cells/mm^2$) + (2.1746 x number of epithelial 317 FoxP3+ cells/mm²) + $(0.1497 \text{ x number of stromal CD14+cells/mm²}) \times 10^{-4})$ and immunoscore^{DSS} 318 = $(0.2744 \text{ x number of stromal PD-L1+ cells/mm}^2) + (-0.1481 \text{ x number of epithelial CD8+})$ 319 $cells/mm^2$) + (-3.160 x number of epithelial FoxP3+ $cells/mm^2$) + (-0.0143 x number of epithelial 320 $CD14+cells/mm^2$) + (0.1436 x number of stromal CD14+cells/mm²) x 10⁻³). Next, the association 321 between immunoscores and survival outcomes was investigated. In multivariate Cox analysis, 322 immunoscore^{PFS} and immunoscore^{DSS} were independent prognosticators of PFS (HR = 5.09, p = 323

(0.001) and DSS (HR = 5.98, p = 0.007) respectively after adjusting for confounders (Figure 3C-324 D). When dichotomizing immunoscores using the maximally selected rank statistics method 325 Kaplan Meier analysis showed that a high immunoscore^{PFS} was associated with poor PFS (log rank 326 test: p < 0.001) and a high immunoscore^{DSS} predicted poor DSS (log rank test: p < 0.001) (Figure 327 3E). The VSCC cohort was then stratified by HPV mRNA ISH status to investigate the prognostic 328 329 contribution of immunoscores within the HPV-independent subgroup. This analysis revealed that a low immunoscore^{PFS} and a low immunoscore^{DSS} significantly predicted favorable PFS (log rank 330 test: p < 0.001) and DSS (log rank test: p < 0.001), respectively in HPV-independent tumors 331 (Figure 3F). In contrast to the maximally selected rank statistics method, only immunoscore^{DSS} 332 was significantly associated with DSS in the entire cohort (log rank test: p = 0.002) when 333 immunoscores were dichotomized by median values (Figure 3G). 334

335

Integration of immunoscores with HPV status and validation of the prognostic models

Drawing upon the prognostic implications of immunoscores and HPV status, we amalgamated 337 these variables to formulate nomograms termed as immunoscore-HPV (IS-HPV) indexPFS and IS-338 HPV index^{DSS} (Figure 4A). Using the nomograms, the probability of an outcome can be predicted 339 340 by calculating a total score based on the points contributed by immunoscore and HPV status predictors. A bootstrap resampling approach was employed to generate 1,000 iterations for internal 341 342 validation of the immunoscore and IS-HPV index models. Calibration plots indicated satisfactory 343 agreement between observed outcomes and predicted outcomes from the nomograms. The IS-HPV index^{PFS} and IS-HPV index^{DSS} concordance (c)-index were 0.752 (corrected c-index: 0.750) and 344 345 0.760 (corrected c-index: 0.752) for PFS and DSS, respectively (Figure 4B). Comparatively, the 346 corrected c-index for HPV status-based models alone was 0.666 for PFS and 0.631 for DSS. For

immunoscore^{PFS} and immunoscore^{DSS} based models the corrected c-index were 0.667 and 0.715 347 for PFS and DSS respectively. To further assess the efficacy of the nomograms an IS-HPV index 348 score was computed for all the patients in the cohort based on coefficients derived from logistic 349 regression models used to construct the nomograms: IS-HPV index^{PFS} score = (1.558 x)350 immunoscore) + (-1.931 x HPV status) and IS-HPV index^{DSS} score = (2.152 x immunoscore) + (-351 2.066 x HPV status). The IS-HPV index scores were then dichotomized based on the maximally 352 selected rank statistics method to select a cutoff (-0.430 for IS-HPV indexPFS and -0.028 for IS-353 HPV index^{DSS}) for Kaplan-Meier analysis. High IS-HPV index^{PFS} and IS-HPV index^{DSS} scores 354 were associated with poor PFS (log rank test: p < 0.001) and DSS (log rank test: p < 0.001) 355 356 respectively (Figure 4C) and an improved discriminatory ability was observed for DSS when comparing the IS-HPV index^{DSS} to HPV status alone (Supplementary Figure 6). Furthermore, 357 decision curve analysis demonstrated a clear net benefit from using the IS-HPV index^{PFS} 358 nomogram when the threshold probability exceeded 0.15 PFS, and consistently across all threshold 359 probabilities for DSS. At clinically relevant threshold probabilities for DSS, the integrated IS-HPV 360 361 index^{DSS} model surpassed the performance of the immunoscore and HPV status models individually (Figure 4D). 362

363

364

365

366

367

368

369

371 Discussion

It is becoming increasingly evident that the efficacy of immunotherapeutic modalities in cancer is 372 affected by the ability to establish an enduring immune response. Indeed, the local immune 373 infiltrate undergoes dynamic changes following treatment and may be indicative of prognosis in 374 375 cancer (12). The association between *in-situ* infiltration of immune cell subsets and survival in 376 VSCC remains unclear and the search for novel biomarkers continues. Here, we developed the 377 first immunoscore model for VSCC by interrogating PD-L1 expression and immune cell 378 infiltration patterns in the epithelium and stroma of tumors. Our analysis revealed that immunoscores independently predict survival in VSCC providing superior prognostication 379 compared to immunological features assessed alone. Furthermore, integrating immunoscores with 380 HPV status and establishing an IS-HPV index improved the prognostic impact of the models. 381

382

VSCC manifests through two distinct molecular pathways: HPV-independent and HPV-associated 383 disease (25). Studies have shown that HPV-independent tumors are associated with poorer survival 384 (10, 11, 26) and novel biomarkers are needed to categorize these cases. Immunoscores are 385 386 prognostic tools focused on tumor immune interactions, that may contribute additional clinical value to traditional staging systems (27). Even though combined risk factor models have been 387 presented for VSCC (28, 29), immunoscores have yet to be explored. In this study low 388 389 immunoscores corresponded with improved PFS and DSS respectively in HPV-independent tumors suggesting that clinical use of immunoscores could improve risk stratification in VSCC. 390 Moreover, immunoscores were independent predictors of survival in the entire VSCC cohort, 391 corroborating findings from other cancer types (30, 31), although the immunological features used 392 to determine the models differed. Previously, immunoscores were established based on infiltration 393

of T cells (19, 27, 32) however in this study myeloid subsets were also included to more accurately 394 reflect the immune landscape. Besides the number of infiltrating immune cells, studies have also 395 396 shown that the spatiotemporal dynamics influence disease progression (33). We therefore spatially resolved immunological features and investigated the epithelial or stromal specific contribution 397 instead of only focusing on the density of cells (34). To accomplish this, IHC and digital 398 399 quantification were used to determine immunoscores. The immunoscores were then integrated with HPV status to form easy-to-use nomograms. At clinically relevant threshold probabilities for 400 401 DSS, our data indicates that using the nomogram may offer additional clinical benefit to VSCC 402 patients compared to HPV status or immunoscore based models alone. Similarly, He et al demonstrated that combining immunoscores with clinicopathological features improved the 403 impact of the models in non-small cell lung carcinoma (NSCLC) (35). Taken together, our findings 404 suggest that the IS-HPV index model could be a rapid and cost-effective diagnostic test to improve 405 406 risk stratification in VSCC and may enable selection of patients who are likely to benefit from less 407 aggressive treatment regimens. Furthermore, the immunoscores may demonstrate predictive value for immunotherapy, as recently reported for NSCLC (36), however we were unable to assess this 408 409 in our cohort as patients had not received immunotherapy.

410

We also assessed the immunological features used to determine immunoscores individually. PD-L1 is pivotal in cancer immunoediting and the expression level impacts patient survival outcomes in many cancer types (37). Consistent with Hecking et al, our data indicates that positive PD-L1 status (TPS > 1) is an independent prognostic factor associated with poor survival, HPVindependent disease (17), and the p53+/p16- subtype. Other studies found no association between epithelial PD-L1 expression and survival (38, 39). The discrepancies may stem from variations in

sample size or methodologies and thresholds used to define PD-L1 status. Considering the rarity
of this disease, a relatively large cohort was recruited in this study and PD-L1 expression was
determined by IHC and digital image analysis instead of manual scoring or genomic profiling. PDL1 status was determined by TPS > 1 contrasting other studies where higher thresholds were used
(18, 39, 40). Future work is needed to harmonize scoring and cut-offs to evaluate the prognostic
importance of PD-L1 in VSCC. Notably, PD-L1 status was discordant when comparing primary
tumors to corresponding recurrent or metastatic lesions, aligning with previous reports (38),

424 indicating it may be important to retest this marker in metastatic or recurrent VSCC.

425

Our data revealed a strong correlation between the number of PD-L1+ cells and infiltration of 426 427 CD68+ macrophages in both the epithelium and stroma of VSCC. Studies have suggested that tumor associated macrophages (TAMs) are the predominant immune cells that express PD-L1 428 429 along with cancer cells in NSCLC and breast cancer (41, 42). The strong correlation we observed 430 may therefore be due to the presence of TAMs expressing CD68+ and PD-L1+ surface markers. Additionally, high stromal infiltration of CD68+ macrophages was linked to HPV-independent 431 tumors and poorer survival outcomes. Condic et al. reported that CD163+ TAMs were an 432 433 unfavorable prognostic variable in VSCC (43). While CD68+ serves as a universal marker for macrophages, CD163+ is predominantly expressed by the M2-polarized subtype. Similar to 434 435 CD68+ macrophages, high stromal CD14+ monocyte infiltration was linked to poor survival and 436 HPV-independent pathogenesis. Van Esch et al showed no significant association between stromal 437 CD14+ infiltration and survival in vulvar epithelial neoplasia lesions, however HPV-independent 438 VSCC cases which constitute most of our cohort, were not assessed in their study (44). In contrast, 439 Abdulrahman et al reported that a strong epithelial CD14+ infiltration was associated with

improved survival (45). Importantly, these cells were negative for other myeloid markers while
our study consisted of a mixed population of CD14+ positive cells. Future work should aim to
decipher the macrophage and monocyte subtypes in our cohort.

443

Lymphocytes, particularly CD8+ T cells, are essential effectors in the adaptive immune response 444 445 against tumors (46). In accordance with other studies, we found no correlation between epithelial CD8+ T cell infiltration and survival in VSCC (47). Conversely, Kortekaas, et al. reported that 446 447 CD3+CD8+Foxp3-T cell infiltration in the epithelial compartments was correlated with favorable 448 survival (15). An earlier study reported no association between this T cell subset and survival, irrespective of dichotomization using median values or ROC analysis (16) highlighting the need 449 450 for further research. Inconsistent with our results, the number of CD3+CD8+FoxP3- and 451 CD3+CD8-FoxP3+ T cells were significantly different when comparing HPV-independent and HPV-associated disease in the abovementioned study. The discrepancies may be due to differences 452 453 in the investigated immune cell subtypes. Although epithelial infiltration of FoxP3+ T cells was associated with improved DSS, independent prognostic value was not observed in this study 454 conflicting with another report (48). Here, the prognostic impact of FoxP3+ was adjusted for HPV 455 456 mRNA ISH instead of p16 IHC as a surrogate marker for HPV. Our group recently demonstrated 457 differences concerning HPV mRNA ISH and p16 IHC for prediction of survival in VSCC (10).

458

This study has limitations such as the retrospective study design and the recruitment of all participants from one single center. To mitigate the limitations, thorough internal validation was conducted. However, multicenter prospective studies are necessary to further confirm the generalizability of our findings. In this study PD-L1 expression and immune cell infiltration were

investigated using IHC and digital image analysis based on established algorithms. A key 463 advantage of this approach is the acquisition of data through unbiased measurements. However, 464 the method faces challenges, including difficulties applying automated workflows to produce 465 accurate results due to biomarker heterogeneity and divergences in tissue samples. Routine 466 calibration with a pathologist was performed to ensure analysis validity. Furthermore, data 467 468 acquired from TMA cores may not be biologically representative due to intra- tumor heterogeneity. We attempted to mitigate the impact of this by averaging two or three cores per case for 469 470 downstream analysis. Additionally, our data demonstrated that the method of dichotomization may 471 influence analysis outcomes. Future studies are therefore required to determine the optimal approach for dichotomizing biomarkers to binary variables (49). 472

473

In summary, this study provides a comprehensive analysis of PD-L1 expression and immune cell infiltration in epithelial and stromal compartments of VSCC. For the first time, we introduce a VSCC immunoscore designed to enhance disease risk stratification. By integrating this immunoscore with HPV status, determined via HPV mRNA ISH, we established an immunoscore-HPV index for prediction of PFS and DSS in VSCC. Additional research is necessary to confirm the accuracy and clinical utility of the immunoscore-HPV index models.

- 480
- 481
- 482
- 483
- 484
- 485

- 486 Abbreviations:
- 487 C-INDEX: concordance-index
- 488 DSS: disease specific survival
- 489 FFPE: formalin-fixed paraffin embedded
- 490 FIGO: the International Federation of Gynecology and Obstetrics
- 491 HPV: human papilloma virus
- 492 HUS: Haukeland University Hospital
- 493 IHC: immunohistochemistry
- 494 ISH: in situ hybridization
- 495 IS-HPV: immunoscore-human papilloma virus index
- 496 LASSO: least absolute shrinkage and selection operator
- 497 PCR: polymerase chain reaction
- 498 PD-1: programmed cell death protein-1
- 499 PD-L1: programmed death ligand protein-1
- 500 PFS: progression free survival
- 501 REK: Regional Committee for Medical and Health Research Ethics
- 502 TIME: tumor immune microenvironment
- 503 TMA: tissue microarray
- 504 VSCC: vulva squamous cell carcinoma

505

506

508 Declarations

509	Ethics approval	and	consent to	particin	oate

- 510 This study was approved by the Regional Committee for Medical and Health Research Ethics
- 511 Norway (REK Nos: 2017/279 and 2014/1907). Written consent was obtained from all participants
- 512 included in this study.
- 513
- 514 **Consent for publication**
- 515 Not applicable

516

517 Availability of data and materials

- 518 Data associated with the findings of this study are included in the article or in the uploaded
- supplementary files and are available from the corresponding author upon reasonable request.

520

521 Competing interests

522 None

523

524 Funding

- 525 This study was supported by The Research Council of Norway through its Centers of Excellence
- 526 funding scheme (DEC, Grant No. 22325 to Center of Excellency for Cancer Biomarkers CCBIO),
- 527 The Western Norway Regional Health Authority (DEC, Helse Vest Grant Nos 912260/2019 and
- 528 F-13105/2024), and the Norwegian Women's Public Health Association (Grant no. 40021).

529

530 Authors' contributions

531	Conceptualization .	, RE, DE	C. LB and HND	: data curation.	RE, LB	and HND:	formal analy	sis.
		,		,	,		, ,	

- 532 RE and HND; funding acquisition, HND, LB and DEC; investigation, RE, IHH, MF, IBMK,
- 533 LCVT and HND; methodology, RE, IHH, MF and HND; project administration, DEC, LB and
- HND; supervision, DEC, LB and HND; validation, RE and HND; visualization, RE, IBMK,
- 535 LVCT; writing—original draft, RE and HND; writing—review & editing, RE, HND, DEC and
- 536 LB. All authors have read and agreed to the published version of the manuscript.

538 Acknowledgements

539 We would like to thank all the patients who participated in this study.

551 References

- 552 1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global
- 553 cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36
- cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63.
- 555 2. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin.

556 2024;74(1):12-49.

557 3. Meltzer-Gunnes CJ, Lie AK, Jonassen CGM, Rangberg A, Nystrand CF, Smastuen MC,

et al. Time trends in human papillomavirus prevalence and genotype distribution in vulvar

carcinoma in Norway. Acta Obstet Gynecol Scand. 2024;103(1):153-64.

- 4. Zach D, Avall-Lundqvist E, Falconer H, Hellman K, Johansson H, Floter Radestad A.
- 561 Patterns of recurrence and survival in vulvar cancer: A nationwide population-based study.
- 562 Gynecol Oncol. 2021;161(3):748-54.

563 5. Nooij LS, Brand FA, Gaarenstroom KN, Creutzberg CL, de Hullu JA, van Poelgeest MI.

Risk factors and treatment for recurrent vulvar squamous cell carcinoma. Crit Rev Oncol
Hematol. 2016;106:1-13.

566 6. Schnack TH, Froeding LP, Kristensen E, Niemann I, Ortoft G, Hogdall E, et al.

567 Preoperative predictors of inguinal lymph node metastases in vulvar cancer - A nationwide
568 study. Gynecol Oncol. 2022;165(3):420-7.

569 7. Soderini A, Aragona A, Reed N. Advanced Vulvar Cancers: What are the Best Options
570 for Treatment? Curr Oncol Rep. 2016;18(10):64.

- 571 8. Weberpals JI, Lo B, Duciaume MM, Spaans JN, Clancy AA, Dimitroulakos J, et al.
- 572 Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct

- 573 Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3. Clin Cancer Res.
 574 2017;23(15):4501-10.
- 575 9. Hinten F, Molijn A, Eckhardt L, Massuger L, Quint W, Bult P, et al. Vulvar cancer: Two
- pathways with different localization and prognosis. Gynecol Oncol. 2018;149(2):310-7.
- 577 10. Dongre HN, Elnour R, Tornaas S, Fromreide S, Thomsen LCV, Kolseth IBM, et al. TP53
- 578 mutation and human papilloma virus status as independent prognostic factors in a Norwegian
- cohort of vulva squamous cell carcinoma. Acta Obstet Gynecol Scand. 2024;103(1):165-75.
- 580 11. Kortekaas KE, Bastiaannet E, van Doorn HC, de Vos van Steenwijk PJ, Ewing-Graham
- 581 PC, Creutzberg CL, et al. Vulvar cancer subclassification by HPV and p53 status results in three
- clinically distinct subtypes. Gynecol Oncol. 2020;159(3):649-56.
- 58312.Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer
- prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662-80.
- 585 13. Santoro A, Angelico G, Inzani F, Arciuolo D, d'Amati A, Addante F, et al. The emerging
- and challenging role of PD-L1 in patients with gynecological cancers: An updating review with
- clinico-pathological considerations. Gynecol Oncol. 2024;184:57-66.
- 588 14. Schwab R, Schiestl LJ, Cascant Ortolano L, Klecker PH, Schmidt MW, Almstedt K, et
- al. Efficacy of pembrolizumab in advanced cancer of the vulva: a systematic review and single-
- arm meta-analysis. Front Oncol. 2024;14:1352975.
- 591 15. Kortekaas KE, Santegoets SJ, Tas L, Ehsan I, Charoentong P, van Doorn HC, et al.
- 592 Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune
- signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy. J Immunother
- 594 Cancer. 2021;9(10).

595 16. Kortekaas KE, Santegoets SJ, Abdulrahman Z, van Ham VJ, van der Tol M, Ehsan I, et

al. High numbers of activated helper T cells are associated with better clinical outcome in early

stage vulvar cancer, irrespective of HPV or p53 status. J Immunother Cancer. 2019;7(1):236.

17. Hecking T, Thiesler T, Schiller C, Lunkenheimer JM, Ayub TH, Rohr A, et al. Tumoral

599 PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral

600 etiology. Oncotarget. 2017;8(54):92890-903.

18. Sznurkowski JJ, Zawrocki A, Sznurkowska K, Peksa R, Biernat W. PD-L1 expression on

602 immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients.

603 Oncotarget. 2017;8(52):89903-12.

19. Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, et al. International

validation of the consensus Immunoscore for the classification of colon cancer: a prognostic andaccuracy study. Lancet. 2018;391(10135):2128-39.

20. Pages F, Andre T, Taieb J, Vernerey D, Henriques J, Borg C, et al. Prognostic and

608 predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in

the prospective IDEA France PRODIGE-GERCOR cohort study. Ann Oncol. 2020;31(7):921-9.

610 21. Argiles G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised

colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann

612 Oncol. 2020;31(10):1291-305.

613 22. Haave H, Gulati S, Brekke J, Lybak S, Vintermyr OK, Aarstad HJ. Tumor stromal

desmoplasia and inflammatory response uniquely predict survival with and without stratification

for HPV tumor infection in OPSCC patients. Acta Otolaryngol. 2018;138(11):1035-42.

616 23. Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, et al.

617 QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878.

- 618 24. Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis
- of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J
- 620 Immunother Cancer. 2019;7(1):278.
- 621 25. Clancy AA, Spaans JN, Weberpals JI. The forgotten woman's cancer: vulvar squamous
- cell carcinoma (VSCC) and a targeted approach to therapy. Ann Oncol. 2016;27(9):1696-705.
- 623 26. Allo G, Yap ML, Cuartero J, Milosevic M, Ferguson S, Mackay H, et al. HPV-
- 624 independent Vulvar Squamous Cell Carcinoma is Associated With Significantly Worse
- Prognosis Compared With HPV-associated Tumors. Int J Gynecol Pathol. 2020;39(4):391-9.
- 626 27. Angell HK, Bruni D, Barrett JC, Herbst R, Galon J. The Immunoscore: Colon Cancer and
- 627 Beyond. Clin Cancer Res. 2020;26(2):332-9.
- 28. Zhang T, Zhu Y, Luo J, Li J, Niu S, Chen H, et al. An integrated model for prognosis in
 vulvar squamous cell carcinoma. BMC Cancer. 2023;23(1):534.
- 630 29. Zhao Z, Zhen S, Liu N, Ding D, Zhang D, Kong J. Survival nomograms for vulvar
- 631 squamous cell carcinoma based on the SEER database and a Chinese external validation cohort.
- 632 Int J Gynaecol Obstet. 2024;165(3):1130-43.
- 633 30. Ghiringhelli F, Bibeau F, Greillier L, Fumet JD, Ilie A, Monville F, et al. Immunoscore
- 634 immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive
- of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer. EBioMedicine.
 2023;92:104633.
- 637 31. Mezheyeuski A, Backman M, Mattsson J, Martin-Bernabe A, Larsson C, Hrynchyk I, et
- al. An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has
- 639 major prognostic impact and predicts immunotherapy response in solid cancers. EBioMedicine.
- 640 2023;88:104452.

641	32.	Han B,	Yim J, Lim	S, Na S,	Lee C, Kim	TM, et al.	Prognostic	Impact of the
			,	, , ,	,	,	<i>L</i>	

- 642 Immunoscore Based on Whole-Slide Image Analysis of CD3+ Tumor-Infiltrating Lymphocytes
- 643 in Diffuse Large B-Cell Lymphoma. Mod Pathol. 2023;36(9):100224.
- 644 33. Mezheyeuski A, Bergsland CH, Backman M, Djureinovic D, Sjoblom T, Bruun J, et al.
- 645 Multispectral imaging for quantitative and compartment-specific immune infiltrates reveals
- distinct immune profiles that classify lung cancer patients. J Pathol. 2018;244(4):421-31.
- 647 34. Nie RC, Yuan SQ, Wang Y, Chen YB, Cai YY, Chen S, et al. Robust immunoscore
- 648 model to predict the response to anti-PD1 therapy in melanoma. Aging (Albany NY).
- 649 2019;11(23):11576-90.
- 650 35. He L, Huang Y, Chen X, Huang X, Wang H, Zhang Y, et al. Development and
- 651 Validation of an Immune-Based Prognostic Risk Score for Patients With Resected Non-Small
- 652 Cell Lung Cancer. Front Immunol. 2022;13:835630.
- 653 36. Hijazi A, Antoniotti C, Cremolini C, Galon J. Light on life: immunoscore immune-
- checkpoint, a predictor of immunotherapy response. Oncoimmunology. 2023;12(1):2243169.
- Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in
 cancer suppression and promotion. Science. 2011;331(6024):1565-70.
- 657 38. Lerias S, Esteves S, Silva F, Cunha M, Cochicho D, Martins L, et al. CD274 (PD-L1),
- 658 CDKN2A (p16), TP53, and EGFR immunohistochemical profile in primary, recurrent and
- metastatic vulvar cancer. Mod Pathol. 2020;33(5):893-904.
- 660 39. Thangarajah F, Morgenstern B, Pahmeyer C, Schiffmann LM, Puppe J, Mallmann P, et
- al. Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva. J Cancer
- 662 Res Clin Oncol. 2019;145(6):1651-60.

- 40. Czogalla B, Pham D, Trillsch F, Rottmann M, Gallwas J, Burges A, et al. PD-L1
- 664 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva. J
- 665 Cancer Res Clin Oncol. 2020;146(3):569-77.
- 41. Liu Y, Zugazagoitia J, Ahmed FS, Henick BS, Gettinger SN, Herbst RS, et al. Immune
- 667 Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway
- Blockade Therapy. Clin Cancer Res. 2020;26(4):970-7.
- 42. Wang L, Guo W, Guo Z, Yu J, Tan J, Simons DL, et al. PD-L1-expressing tumor-
- associated macrophages are immunostimulatory and associate with good clinical outcome in
- 671 human breast cancer. Cell Rep Med. 2024;5(2):101420.
- 43. Condic M, Rohr A, Riemann S, Staerk C, Ayub TH, Doeser A, et al. Immune Profiling of
- 673 Vulvar Squamous Cell Cancer Discovers a Macrophage-rich Subtype Associated with Poor
- 674 Prognosis. Cancer Res Commun. 2024;4(3):861-75.
- 44. van Esch EM, van Poelgeest MI, Trimbos JB, Fleuren GJ, Jordanova ES, van der Burg
- 676 SH. Intraepithelial macrophage infiltration is related to a high number of regulatory T cells and
- promotes a progressive course of HPV-induced vulvar neoplasia. Int J Cancer. 2015;136(4):E85-
- 678 94.
- 45. Abdulrahman Z, Kortekaas KE, Welters MJP, van Poelgeest MIE, van der Burg SH.
- 680 Monocyte infiltration is an independent positive prognostic biomarker in vulvar squamous cell
- carcinoma. Cancer Immunol Immunother. 2024;73(9):166.
- 46. Raskov H, Orhan A, Christensen JP, Gogenur I. Cytotoxic CD8(+) T cells in cancer and
- 683 cancer immunotherapy. Br J Cancer. 2021;124(2):359-67.

- 47. Burandt E, Blessin NC, Rolschewski AC, Lutz F, Mandelkow T, Yang C, et al. T-Cell
- 685 Density at the Invasive Margin and Immune Phenotypes Predict Outcome in Vulvar Squamous
- 686 Cell Cancer. Cancers (Basel). 2022;14(17).
- 48. Arik D, Benli T, Telli E. Number of FoxP3+ regulatory T-cells are associated with
- recurrence in vulvar squamous cell carcinoma. J Gynecol Oncol. 2023;34(2):e16.
- 49. Prince Nelson SL, Ramakrishnan V, Nietert PJ, Kamen DL, Ramos PS, Wolf BJ. An
- 690 evaluation of common methods for dichotomization of continuous variables to discriminate
- disease status. Commun Stat Theory Methods. 2017;46(21):10823-34.



694 Figure 1: PD-L1 expression and immune cell infiltration in VSCC. (A) Representative immunohistochemical staining of CD4+, CD8+, CD68+, CD14+, FoxP3+, and PD-L1+ cells. 695 Scale bar = 50 μ m. (B) Box plots depicting differences in the number of cells per mm² based on 696 FIGO stage. (C) Box plots depicting differences in the number of cells per mm² based on HPV 697 status, as determined by HPV mRNA ISH, within the advanced VSCC subgroup (FIGO stage 698 699 III/IV). p-values < 0.05 were considered statistically significant. The box shows the interquartile range, and medians are highlighted with a black line. Individual cases are represented by black 700 dots. (D) Matrix showing correlations between immune subsets. Spearmans' rank correlation 701 702 coefficients (p) are provided in each box of the matrix. Larger circles with darker shades of blue 703 demonstrate stronger positive correlations. Correlations that were not statistically significant (p > 1704 0.05) are shown as blank. Scatterplots with fitted regression lines and 95% confidence interval 705 showing correlations between PD-L1+ and CD68+ cells in (E) epithelial and (F) stromal 706 compartments.



Figure 2: Prognostic value of PD-L1 status and immune cell infiltration. Kaplan-Meier curves demonstrating influence of PD-L1 status and stromal CD68+ or CD14+ infiltration on (A) progression free- and (B) disease specific survival. p-values < 0.05 were considered statistically significant based on the log rank test. Representative immunohistochemical staining of cases with discordant PD-L1 expression in primary tumors and corresponding (C) recurrences or (D) metastatic lesions. Scale bar = $50 \mu m$. PD-L1 status patterns in primary tumors and matched (E)

714 recurrences or (F) metastatic lesions.



716 Figure 3: Determining immunoscores based on the LASSO cox regression model. (A) Immune feature selection for prediction of PFS by applying 10-fold cross-validation and training a LASSO 717 regression model. The dotted vertical lines indicate selected λ values using minimum criteria. (B) 718 719 Regression coefficient profiles of epithelial and stromal CD4+, CD8+, CD68+, CD14+, FoxP3+, and PD-L1+ subsets in the LASSO regression model. Forest plots demonstrating the association 720 of immunescores and clinicopathological features on (D) PFS and (E) DSS. Hazard ratios (HR) 721 with 95% confidence interval (C.I.) and p-values are shown. Kaplan-Meier curves showing the 722 influence of immunoscores, dichotomized by the maximally selected rank statistics (maxstat*) 723 724 method, on PFS and DSS for the (E) entire cohort and (F) HPV-independent subgroup. (G) Kaplan-Meier curves showing the influence of immunoscores, dichotomized by median values, on PFS 725 726 and DSS for the entire cohort



727

Figure 4: Construction of immunoscore-HPV index nomograms. (A) Immunoscore-HPV (IS-HPV) index nomograms for PFS and DSS. (B) Calibration plots demonstrating the agreement between nomogram predicted outcomes and actual survival outcomes. Concordance index (cindex) and corrected (corr) c-index values are provided. IS-HPV index scores were calculated for the entire VSCC cohort using coefficients from the logistic regression model and dichotomized based on the maximally selected rank statistics method. (C) Kaplan-Meier curves showing the

734	influence of IS-HPV index on PFS and DSS. (D) Decision curve analysis for the nomograms for
735	PFS and DSS.
736	
737	
738	
739	
740	
741	
742	
743	
744	
745	
746	
747	
748	
749	
750	
751	
752	
753	
754	
755	
756	

Table 1: Influence of PD-L1 status and immune cell infiltration on progression free- and disease

specific survival. In the multivariate analysis PFS was adjusted for age and HPV mRNA ISH. DSS

vas adjusted for age, tumor size, and HPV mRNA ISH.

Progression free survival		Univari	iate analysis	Multivariate analysis			
		HR	(95% CI)	p- value	HR	(95% CI)	p- value
PD-L1	$TPS \\ \ge 1$	2.349	1.342-4.112	0.003	1.802	1.024-3.170	0.041
PD-L1	$CPS \\ \ge 1$	2.000	0.975-4.106	0.059	-	-	-
CD4	High epithelial Infiltration	0.969	0.565-1.662	0.908	-	-	-
	High stromal Infiltration	0.874	0.509-1.500	0.625	-	-	-
CD8	High epithelial Infiltration	0.831	0.483-1.429	0.503	-	-	-
	High stromal Infiltration	0.994	0.580-1.705	0.983	-	-	-
CD68	High epithelial Infiltration	1.754	1.014-3.031	0.044	1.532	0.880-2.667	0.132
	High stromal Infiltration	1.920	1.107-3.330	0.020	1.497	0.861-2.604	0.153
CD14	High epithelial Infiltration	1.488	0.864-2.561	0.151	-	-	-
	High stromal Infiltration	1.957	1.131-3.387	0.016	1.578	0.893-2.789	0.116
FOXP3	High epithelial Infiltration	0.808	0.471-1.386	0.439	-	-	-
	High stromal Infiltration	0.983	0.574-1.685	0.951	-	-	-
Disease specific survival		Univari	iate analysis		Multiv	ariate analysis	
		HR	(95% CI)	p- value	HR	(95% CI)	p- value

PD-L1	TPS ≥ 1	1.878	0.816-4.323	0.139	-	-	-
PD-L1	$CPS \ge 1$	1.479	0.546-4.001	0.441	-	-	-
CD4	High epithelial Infiltration	0.782	0.342-1.790	0.561	-	-	-
CD4	High stromal Infiltration	0.765	0.335-1.745	0.524	-	-	-
CD8	High epithelial Infiltration	0.651	0.281-1.506	0.316	-	-	-
	High stromal Infiltration	1.126	0.496-2.555	0.776	-	-	-
CD68	High epithelial Infiltration	1.541	0.673-3.529	0.307	-	-	-
	High stromal Infiltration	2.995	1.241-7.225	0.015	1.944	0.796-4.751	0.145
CD14	High epithelial Infiltration	1.149	0.505-2.615	0.741	-	-	-
	High stromal Infiltration	2.566	1.083-6.081	0.032	1.526	0.597-3.899	0.378
FOXP3	High epithelial Infiltration	0.397	0.163-0.966	0.042	0.533	0.215-1.317	0.173
	High stromal Infiltration	0.868	0.383-1.969	0.736	-	-	-

Table 2: Relationship between PD-L1 status, as determined by TPS > 1, and clinicopathological

763 features.

Parameters	PD-L1 Status							
	n=117	Positive (%)	Negative (%)	χ2 (p-value)				
Age								
< 71 years	57 (48.7%)	24 (20.5%)	33 (28.2%)	3.079				
\geq 71 years	60 (51.3%)	35 (29.9%)	25 (21.4%)	(0.079)				
BMI								
Normal	31 (26.5%)	13 (11.1%)	18 (15.4%)	1.462				
Overweight/obese	54 (46.2%)	30 (25.6%)	24 (20.5%)	(0.227)				
Unknown	32 (27.3%)	15 (12.8%)	17 (14.5%)					
FIGO stage								
Stage I & II	78 (66.7%)	35 (29.9%)	43 (36.8%)	2.889				
Stage III & IV	39 (33.3%)	24 (20.5%)	15 (12.8%)	(0.089)				
Tumor size								
\leq 4cm	81 (69.2%)	37 (31.6%)	44 (37.6%)	2.374				
> 4cm	36 (30.8%)	22 (18.8%)	14 (12.0%)	(0.123)				
Lymph node metastasis								
No	79 (67.5%)	35 (29.9%)	44 (37.6%)	3.649				
Yes	38 (32.5%)	24 (20.5%)	14 (12.0%)	(0.056)				
HPV DNA								
Negative	82 (70.1%)	49 (41.9%)	33 (28.2%)	9.543				
Positive	35 (29.9%)	10 (8.5%)	25 (21.4%)	(0.002)				
HPV mRNA ISH								
Negative	87 (74.4%)	51 (43.6%)	36 (30.8%)	9.112				
Positive	30 (25.6%)	8 (6.8%)	22 (18.8%)	(0.003)				
p53/p16								
p53+/p16-	54 (46.2%)	34 (29.1%)	20 (17.1%)	7.891				
p53-/p16+	34 (29.1%)	11 (9.4%)	23 (19.7%)	(0.019)				
p53-/p16-	29 (24.8%)	14 (12.0%)	15 (12.8%)	· · · ·				
Recurrence of cancer	× ,		× /					
No	79 (67.5%)	35 (29.9%)	44 (37.6%)	3.649				
Yes	38 (32.5%)	24 (20.5%)	14 (12.0%)	(0.056)				
Death caused by VSCC		× /	× /	× /				
No	94 (80.3%)	46 (39.3%)	48 (41.0%)	0.425				
Yes	23 (19.7%)	13 (11.1%)	10 (8.5%)	(0.514)				